Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Puts Squeeze On SnugZ; Promo Product/OTC Drug Manufacturer Warned For CGMP Violations

Executive Summary

Known for its customizable lanyards and eyewear retainers, SnugZ USA, Inc. also manufactures sunscreens and other personal-care items for corporate branding purposes. The FDA inspected the firm’s West Jordan, Utah facility in late 2018, finding significant violations of current good manufacturing practices, according to a warning letter posted to the agency’s website 9 July.

You may also be interested in...

Sunscreens, Sanitizers In Tootsie Roll And Other Novelty Packaging Recalled

FDA also imposes import alert on lip balms, hand sanitizers and sunscreens made by Ningbo HuiZe Commodity in Zhejiang, China. Alert subjects products to detention without physical examination at US international ports of entry.

Skin Care Firms Get External Analgesic Treatment In FDA Warning Letters

Firms marketed products with label and other claims rendering them drugs but containing ingredients and label indications not part of OTC external analgesic TFM, recent warning letters say. Each firm also advised about GMP problems based on findings from Office of Regulatory Affairs' inspections and asked to hire regulatory consultants and provide detailed CAPAs.

US And Trading Neighbors Advocate Risk-Based, Science-Backed Cosmetics Regs

As European industry’s concerns grow about “politicization” of regulatory programs, the United States-Mexico-Canada Agreement’s cosmetics annex directs regulatory authorities pursuing new rules to give due consideration to scientific and technical guidance documents developed through international collaboration.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts